EXEL - Exelixis Inc. (EXEL) Q4 2023 Earnings Call Transcript
2024-02-06 22:13:03 ET
Exelixis, Inc. (EXEL)
Q4 2023 Earnings Conference Call
February 06, 2024, 05:00 PM ET
Company Participants
Susan Hubbard - EVP, Public Affairs and IR
Mike Morrissey - President and CEO
Chris Senner - CFO
PJ Haley - EVP, Commercial
Dana Aftab - Chief Scientific Officer
Amy Peterson - Chief Medical Officer
Conference Call Participants
Michael Schmidt - Guggenheim
Chi Meng Fong - Bank of America
Asthika Goonewardene - Truist
Andy Hsieh - William Blair
Joyce Zhou - TD Cowen
Akash Tewari - Jefferies
Silvan Tuerkcan - JMP Securities
Michael Reid - Morgan Stanley
Etzer Darout - BMO Capital Markets
Peter Lawson - Barclays
Kaveri Pohlman - BTIG
Christopher Liu - the Leerink Partners
Presentation
Operator
Good day, ladies and gentlemen, and welcome to the Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results Conference Call. My name is Tawanda, and I will be your operator for today. As a reminder, this call is being recorded for replay purposes.
I would now like to turn the call over to your host today, Ms. Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations. Please proceed.
Susan Hubbard
Thank you, Tawanda. And thank you all for joining us for the Exelixis fourth quarter and fiscal year 2023 financial results conference call. Joining me on today's call are Mike Morrissey, our President and CEO; and Chris Senner, our Chief Financial Officer, who will review our progress for the fourth quarter and full year 2023 ended December 29th, 2023. PJ Haley, our Executive Vice President of Commercial; Amy Peterson, our Chief Medical Officer, and Dana Aftab, our Chief Scientific Officer are also on the call today and will participate in the question-and-answer portion of the call.
During the call today, we will refer to financial measures not calculated according to generally accepted accounting principles. Please refer to today's press release which is posted on our website for an explanation of our reasons for using such non-GAAP measures, as well as tables deriving these measures from our GAAP results. During the course of this presentation, we will be making forward-looking statements regarding future events and the future performance of the company. This includes statements about possible developments regarding discovery, product development, regulatory, commercial, financial and strategic matters.
Actual events or results could of course differ materially. We refer you to the documents we file from time-to-time with the SEC, which under the heading Risk Factors identify important factors that could cause actual results to differ materially from those expressed in by the company verbally and in writing today, including, without limitation, risks and uncertainties related to product commercial success, market competition, regulatory review and approval processes, conducting clinical trials, compliance with applicable regulatory requirements, our dependence on collaboration partners, and the level of costs associated with discovery, product development, business development and commercialization activities.
And with that, I will turn the call over to Mike.
Mike Morrissey
All right. Thank you, Susan, and thanks to everyone for joining us on the call today....
Exelixis, Inc. (EXEL) Q4 2023 Earnings Call Transcript